ANO1 and prostate cancer: Recently, TMEM16A has been reported to be highly expressed in many human tumors including breast cancer [42, 43], HNSCC [44–47], colorectal cancer (CRC) [48, 49], ESCC [50], lung cancer [51], hepatocellular carcinoma [52], prostate cancer [53], gastric cancer [54, 55], and glioma [56] (Table 1).